Kaleido Biosciences, Inc. (KLDO) Research

Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.

Market snapshot

Symbol
KLDO
Price
$0.00
Day change
0.00%
Market cap
$4.3K
P/E ratio
-0.00x
52-week range
0.00001-0.20005
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Arno Therapeutics, Inc. (ARNI)
  • Better Therapeutics, Inc. (BTTX)
  • Baudax Bio, Inc. (BXRXQ)
  • Calithera Biosciences, Inc. (CALA)
  • Innovation1 Biotech Inc. (IVBT)
  • Sienna Biopharmaceuticals, Inc. (SNNAQ)
  • TetraLogic Pharmaceuticals Corporation (TLOG)
  • Tengion, Inc. (TNGNQ)

Recent insider activity

  • van Hylckama Vlieg Johan — F-InKind (2087 shares) on 2022-02-28
  • Korn Jerald — F-InKind (2046 shares) on 2022-02-28
  • van Hylckama Vlieg Johan — A-Award (350000 shares) on 2022-01-14
  • Long Alison S — A-Award (125000 shares) on 2022-01-14
  • Long Alison S — A-Award (46800 shares) on 2022-01-14

Open Kaleido Biosciences, Inc. (KLDO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.